BioNTech SE/$BNTX

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About BioNTech SE

BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and antibody-drug conjugates, or ADCs. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. Covid vaccine Comirnaty is its first commercialized product.

Ticker

$BNTX
Primary listing

Industry

Biotechnology
Headquarters

Employees

6,772

ISIN

US09075V1026

BioNTech SE Metrics

BasicAdvanced
$27B
-
-$3.74
1.28
-

What the Analysts think about BioNTech SE

Analyst ratings (Buy, Hold, Sell) for BioNTech SE stock.

Bulls say / Bears say

BioNTech's strategic investments in immunotherapy, including the development of BNT327 for breast cancer treatment, position the company to capture significant market share in the oncology sector. (TipRanks)
The company's robust pipeline, featuring multiple late-stage oncology programs, underscores its commitment to addressing unmet medical needs and diversifying revenue streams beyond COVID-19 vaccines. (Wikipedia)
Analysts have set an average price target of $140.10 for BioNTech, indicating a potential upside of approximately 11.43% from the current price, reflecting confidence in the company's growth prospects. (TipRanks)
BioNTech reported a net loss of €665 million in 2024, a significant decline from a profit of €9.4 billion in 2022, raising concerns about its financial stability. (Wikipedia)
The company's forward P/E ratio stands at -22.30, reflecting expectations of negative earnings in the near term, which may deter potential investors. (DirectorsTalkInterviews)
BioNTech's free cash flow is negative at -$335.98 million, indicating substantial cash outflows to sustain its extensive research and development efforts, which could impact its financial flexibility. (DirectorsTalkInterviews)
Data summarised monthly by Lightyear AI. Last updated on 7 Jul 2025.

BioNTech SE Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

BioNTech SE Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $BNTX

Sign up or log in to buy
Capital at risk
Market closedADR

Upcoming events

No upcoming events
FAQs